Healthcare Industry News: Merck
News Release - September 6, 2018
SiteOne Therapeutics Appoints John Hunter, Ph.D. as Chief Scientific OfficerBOZEMAN, Mont., Sept. 6, 2018 -- (Healthcare Sales & Marketing Network) -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the appointment of John Hunter, Ph.D., as Chief Scientific Officer. Dr. Hunter is a highly-accomplished pharmaceutical research and development executive, having held multiple leadership positions within the pharmaceutical industry at Merck, Schering-Plough, Roche and Parke-Davis over the span of his 30-year career. In his role, Dr. Hunter will be responsible for advancing SiteOne's portfolio of non-opioid drug candidates for the treatment of pain.
"John is a notable addition to our management team. His decision to join SiteOne at this stage in his career attests to our unique platform of first-in-class, highly potent and selective Nav1.7 inhibitors," said Stan Abel CEO of SiteOne Therapeutics. "John has a wealth of knowledge in both neuroscience and drug development. His expertise will be invaluable as our pipeline of novel pain therapeutics progresses toward the clinic and our discovery platform continues to explore new indications."
Prior to joining SiteOne Therapeutics, Dr. Hunter was most recently Vice-President of Research Science and Head of Discovery Research for the Cardio-Renal Therapeutic Area at Merck. Further roles within Merck included Vice President of Global Pharmacology, Screening & Protein Sciences and Vice-President and West Point Site Head for Discovery Research focused on the Neuroscience and Infectious Disease Therapeutic Areas. He was previously Vice-President of Neuroscience at Schering-Plough and Department Head of Pain Research and Systems Pharmacology at Roche Bioscience. During the course of his career, Dr. Hunter led multiple Discovery Research Project teams as well as early and late stage Clinical Development teams.
Dr. Hunter has published extensively, having authored more than 100 original scientific articles. He is currently a member of the International Association for the Study of Pain (IASP) and the Society for Neuroscience.
"SiteOne's approach to targeting the Nav1.7 sodium ion channel is very unique and has tremendous potential to improve the standard of care in pain therapy," said Dr. Hunter. "This is a very exciting time for SiteOne, and I look forward to working with the leadership team to achieve our goal of transforming the landscape of pain management."
About SiteOne Therapeutics, Inc.
SiteOne Therapeutics is a biopharmaceutical company headquartered in Bozeman, Montana with a research laboratory in South San Francisco, California. Since its inception, SiteOne has been dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the significant addiction potential and side-effects of opioids. The company's therapeutic candidates are highly selective sodium ion channel 1.7 (Nav1.7) inhibitors based on naturally occurring small molecules. Given the urgent need for new, non-opioid solutions for managing pain, SiteOne is focused on advancing its lead product candidates for multiple therapeutic applications.
Source: SiteOne Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.